| A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients With BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) and High-Risk NMIBC Patients Who Are BCG Naïve or Received Incomplete BCG Treatment |
Nature and Objective:
This Phase 1/2 study evaluates the safety, tolerability, and preliminary efficacy of EG-70, a novel non-viral gene therapy, administered intravesically in patients with non-muscle invasive bladder cancer (NMIBC) who are unresponsive to Bacillus Calmette-Guérin (BCG) or have received incomplete BCG treatment. The study includes a dose-escalation phase to determine the recommended Phase 2 dose, followed by an efficacy phase assessing tumor response and durability of effect
Stade de la Maladie: Précoce
Organe: Vessie
Maladie: Cancer de la vessie